Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC

被引：0
|
作者：
Lee, M. [1 ]
Miao, E. [2 ]
Zhang, C. [2 ]
Xue, X. [2 ]
Tuckman, S. [3 ]
Halmos, B. [1 ]
Cheng, H. [1 ]
机构：
[1] Montefiore Einstein Canc Ctr MECC, Bronx, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Bronx, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Osimertinib adherence; NSCLC; Socioeconomic healthcare; disparities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-04
引用
收藏
页码：S331 / S332
页数：2
相关论文
共 50 条
  • [41] Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
    Lin, Lishi
    Smit, Egbert F.
    de Langen, Adrianus J.
    van Balen, Dorieke E. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    TARGETED ONCOLOGY, 2022, 17 (01) : 53 - 59
  • [42] Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors.
    Ulivi, Paola
    Petracci, Elisabetta
    Dazzi, Claudio
    Verlicchi, Alberto
    Canale, Matteo
    Chiadini, Elisa
    Capelli, Laura
    Gamboni, Alessandro
    Papi, Maximilian
    Burgio, Marco Angelo
    Mariotti, Marita
    De Luigi, Nicoletta
    Ludovini, Vienna
    Bennati, Chiara
    Chiari, Rita
    Crino, Lucio
    Amadori, Dino
    Delmonte, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study
    Kato, T.
    Dong, X.
    Takahashi, T.
    Soparattanapaisarn, N.
    Geater, S. L.
    Nguyen, K. V.
    Wang, C. L.
    Arriola, E.
    Moiseenko, F.
    Thompson, L.
    Harker, S.
    Grainger, E.
    Armenteros-Monterroso, E.
    Bolanos, A.
    Ramalingam, S.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S36 - S36
  • [44] Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
    Lishi Lin
    Egbert F. Smit
    Adrianus J. de Langen
    Dorieke E. M. van Balen
    Jos H. Beijnen
    Alwin D. R. Huitema
    Targeted Oncology, 2022, 17 : 53 - 59
  • [45] Postoperative Chemotherapy-Use and Results of the ADAURA-Study: Osimertinib as adjuvant Therapy in resected EGFR-mutated NSCLC Patients
    Grohe, C.
    Wu, Y. L.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S.
    Kato, T.
    Laktionov, K.
    Vu, H. V.
    Wang, Z.
    Lu, S.
    Lee, K.
    Akewanlop, C.
    Yu, C. J.
    De Marinis, F.
    Bonanno, L.
    Domine, M.
    Shepherd, F. A.
    Zeng, L.
    Atasoy, A.
    Herbst, R. S.
    Tsuboi, M.
    Engel-Riedel, W.
    PNEUMOLOGIE, 2021, 75 : S18 - S19
  • [46] Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
    Li, X.
    Zheng, X.
    An, J.
    Hua, Y.
    Ding, X.
    Shi, H.
    Xu, W.
    Li, Y.
    Zhou, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [47] The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials
    Tang, Xiumei
    Li, Weimin
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [48] Association of PD-L1 tumor proportion score=20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC
    Hamakawa, Yusuke
    Agemi, Yoko
    Shiba, Aya
    Ikeda, Toshiki
    Higashi, Yuko
    Aga, Masaharu
    Miyazaki, Kazuhito
    Taniguchi, Yuri
    Misumi, Yuki
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Saigusa, Yusuke
    Kobayashi, Nobuaki
    Okamoto, Hiroaki
    Kaneko, Takeshi
    CANCER MEDICINE, 2023, 12 (17): : 17788 - 17797
  • [49] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
    Rotow, Julia K.
    Costa, Daniel Botelho
    Paweletz, Cloud P.
    Awad, Mark M.
    Marcoux, Paul
    Rangachari, Deepa
    Barbie, David Allen
    Sands, Jacob
    Cheng, Michael L.
    Johnson, Bruce E.
    Oxnard, Geoffrey R.
    Jackman, David Michael
    Kwiatkowski, David J.
    Kehl, Kenneth L.
    Izdebski, Monika D.
    Lau, Christie J.
    Vasquez, Kevin A.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Ou, Xiaoling
    Walding, Andrew
    Dymond, Angela W.
    Ren, Song
    Cantarini, Mireille
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723
12345